SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, November 13, 2024, at 8:00 a.m. ET to discuss its third quarter 2024 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event here.
In addition, ARS Pharma Management will be participating in multiple upcoming investor conferences:
To access the live and archived webcasts for the third quarter 2024 earnings conference call and investor conferences, please visit the Events & Presentations page in the “Investors & Media” section of the Company’s website. A replay of the each of the webcasts will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® 2 mg (trade name EURneffy® in the European Union (EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contacts:
Justin Chakma, ARS Pharmaceuticals
This email address is being protected from spambots. You need JavaScript enabled to view it.
Alex Straus, THRUST
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Christy Curran, Sam Brown Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.60 |
| Daily Change: | 0.81 5.87 |
| Daily Volume: | 4,038,219 |
| Market Cap: | US$1.440B |
August 13, 2025 March 20, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
